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The severe combined immunodeficiency disorder (SCID)-beige/albumin (Alb)-urokinase plasminogen activator (uPA)
mouse containing a human-mouse chimeric liver is currently the only small animal model capable of supporting
hepatitis C virus (HCV) infection. This model was utilized to characterize the host transcriptional response to HCV
infection. The purpose of these studies was to investigate the genetic component of the host response to HCV infection
and also to distinguish virus-induced gene expression changes from adaptive HCV-specific immune-mediated effects.
Gene expression profiles from HCV-infected mice were also compared to those from HCV-infected patients. Analyses of
the gene expression data demonstrate that host factors regulate the response to HCV infection, including the nature of
the innate antiviral immune response. They also indicate that HCV mediates gene expression changes, including
regulation of lipid metabolism genes, which have the potential to be directly cytopathic, indicating that liver pathology
may not be exclusively mediated by HCV-specific adaptive immune responses. This effect appears to be inversely
related to the activation of the innate antiviral immune response. In summary, the nature of the initial interferon
response to HCV infection may determine the extent of viral-mediated effects on host gene expression.
Citation: Walters KA, Joyce MA, Thompson JC, Smith MW, Yeh MM, et al. (2006) Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model:
Role of the innate antiviral immune response. PLoS Pathog 2(6): e59. DOI: 10.1371/journal.ppat.0020059
Introduction
Hepatitis C virus (HCV) is a blood-borne pathogen
belonging to the Flaviviridae family. There are over 170
million people worldwide chronically infected with HCV. The
natural history of HCV infection is highly variable and
approximately 30% of chronically infected patients will
develop progressive liver disease, including ﬁbrosis, cirrhosis,
and hepatocellular carcinoma (HCC) [1]. Although exposure
to HCV generally results in chronic infection, individuals can
often be infected for decades with minimal liver damage,
suggesting that the effect of HCV on hepatocyte function is
extremely subtle. In addition, the high variability in HCV-
associated liver disease, ranging from mild inﬂammation to
rapidly progressive ﬁbrosis, suggests that host factors play an
important role in both infection outcome and viral patho-
genesis. It is generally thought that the pathology associated
with chronic HCV infection is mediated by an HCV-speciﬁc
cell-mediated immune response [2]. The role of HCV
replication, and subsequent virus-host interactions, in the
pathology of chronic infection remains unclear. Several
studies have attempted to probe the complexity of HCV-host
interactions by performing global transcriptional proﬁling
on liver biopsy samples from HCV-infected individuals and
chimpanzees [3–9]. Not surprisingly, these studies have
revealed substantial variation in the host response to
infection. There are several possible contributing factors to
this variation, including duration of infection, extent of liver
disease, and viral factors including genotype and quasispecies
diversity. This makes it difﬁcult to assess the individual role
that host factors play in this variation. In addition, these
studies are complicated by the presence of an HCV-speciﬁc
adaptive immune response, making it difﬁcult to distinguish
immune-mediated and viral-induced gene expression
changes.
In the current study, the severe combined immunodeﬁ-
ciency disorder (SCID)-beige/albumin (Alb)-urokinase plas-
minogen activator (uPA) mouse model was used to investigate
how host-speciﬁc factors inﬂuence the host response to HCV
infection. These animals are derived by transplantation of
normal human hepatocytes into SCID mice carrying a
plasminogen activator transgene (Alb-uPA) [10–13]. The
model has signiﬁcant advantages over in vitro systems in that
it represents an in vivo infection, all HCV proteins are
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virions are assembled and released from hepatocytes.
Together with the use of highly sensitive oligonucleotide
microarray technology, this model provides several features
that make it a unique system in which to study HCV-host
interactions. First, because these animals are transplanted
with hepatocytes from different donors, there is the
opportunity to analyze host-speciﬁc responses to HCV.
Second, both viral inoculum and duration of infection can
be controlled, making it easier to interpret the cause of
variation in the global gene expression proﬁles. Finally, the
lack of an adaptive immune response in these animals makes
it possible to distinguish viral-mediated from immune-
mediated effects on host gene expression.
Cohorts of mice transplanted with hepatocytes from
different donors were inoculated with a single source of
HCV. Gene expression proﬁling of liver tissue was then
performed to characterize the host response to infection. The
results indicate that host factors do contribute to the
variation in host response to HCV infection and that the
nature of the initial innate antiviral immune response may
determine the extent of viral-mediated effects on host gene
expression.
Results
Host Factors Influence the Response to HCV Infection in
the SCID-beige/Alb-uPA Mouse
Chronic HCV infection results in a highly variable course
of liver disease, ranging from mild inﬂammation maintained
over decades to rapidly progressive ﬁbrosis, cirrhosis, and
HCC. Even when patients are infected with the same
genotype, severe liver disease occurs in only a subset of
chronically infected individuals, suggesting that host factors
likely play an important role in the progression of liver
disease [14,15]. In order to investigate the contribution of
host factors in the response to infection, cohorts of mice
transplanted with hepatocytes from different donors were
infected with a single source of HCV (þ) patient serum
(genotype 1a). At 4 to 7 wk after exposure to HCV, the
animals were killed, and the human liver hepatocytes were
isolated and characterized as outlined in Materials and
Methods. Information regarding serum HCV levels, duration
of infection, and purity of liver samples is shown in Table 1.
Gene expression microarray experiments were then per-
formed to characterize the host response to HCV infection.
However, since liver samples from these animals typically had
small percentages of contaminating mouse liver tissue (Table
1), the level of cross-hybridization of mouse liver mRNA to
the human probes present on the microarray was ﬁrst
assessed [58]. The small set of genes identiﬁed (less than 2%
of genes on the array) were either removed from subsequent
analysis of gene expression data or changes in the expression
of these genes were validated using human-speciﬁc quantita-
tive real-time (RT)-PCR.
For the microarray experiments, mRNA samples isolated
from four HCV-infected animals containing hepatocytes
from three different donors were compared to mRNA
isolated from their donor-matched uninfected controls.
Because each pair of mice contained hepatocytes from the
same donor, changes in gene expression should mainly be
induced by the HCV infection and independent of host
variation. In general, the effect on host gene expression by
HCV infection was not that extreme, with 390 genes showing
a 2-fold or higher change in expression (p   0.05) in at least
two experiments (Figure 1). This is similar to what is observed
during acute HCV infection in chimpanzees [6]. The grouping
of experiments by the clustering algorithm suggested that the
effect on host gene expression was similar between mice
containing the same donor hepatocytes. In contrast, the
effect on host gene expression appeared quite different
between mice containing different donor hepatocytes. The
correlation coefﬁcient for common differentially regulated
Table 1. Characteristics of Mouse Liver Samples
Donor Mouse HAAT Serum HCV
Titers
Duration of
Infection
Human
A A685 450 1.3 3 10
7 6w k 8 0
B B473(1) 1,006 6.1 3 10
6 7w k 8 8
B B473(2) 1,006 6.1 3 10
6 7w k 7 8
B B473(3) 1,006 6.1 3 10
6 7w k 8 1
B B497 440 Naı ¨ve N/A 85
C C569 812 3.0 3 10
5 2w k 8 5
C C585(1) 361 8.8 3 10
6 6w k 8 5
C C585(2) 361 8.8 3 10
6 6w k 7 7
C C582 1,022 Naı ¨ve N/A 87
C C572 426 1.2 3 10
7 6w k 7 7
C C584 598 Naı ¨ve N/A 78
D D196 414 1.9 3 10
6 4w k 8 0
D D198 686 Naive N/A 79
E E705 568 4.9 3 10
5 10 wk 70
HAAT indicates human alpha-1 anti-trypsin (lg/ml), HCV titers are genomes/ml, and %
Human indicates what portion of the dissected mouse liver sample is human based on
semiquantitative PCR analysis of succinyl CoA ligase gene (details in Materials and
Methods). All mice were inoculated with serum from the same patient (genotype 1a). The
mouse nomenclature indicates the donor (letter) followed by the mouse ID (number).
Multiple samples from a single liver are identified by (number) following the mouse ID.
DOI: 10.1371/journal.ppat.0020059.t001
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Host-Specific Response to HCV Infection
Synopsis
The natural history of hepatitis C virus (HCV) infection is highly
variable, and approximately 30% of chronically infected patients will
develop progressive liver disease, including fibrosis, cirrhosis, and
hepatocellular carcinoma (HCC). This high variability in HCV-
associated liver disease, ranging from mild inflammation to rapidly
progressive fibrosis, suggests that host factors play an important
role in both infection outcome and viral pathogenesis. In the current
study, the severe combined immunodeficiency disorder-beige/
albumin-urokinase plasminogen activator mouse model was used
to investigate how host-specific factors influence the host response
to HCV infection. Cohorts of mice transplanted with hepatocytes
from different donors were inoculated with a single source of HCV.
Gene expression profiling was performed to characterize the host
response to infection. The results indicate that host factors do
contribute to the variation in host response to HCV infection,
including the activation of innate antiviral signaling pathways. They
also suggest that the nature of the innate antiviral immune response
during the acute phase of infection may determine the extent of
viral-mediated effects on host gene expression, including regulation
of lipid metabolism genes and induction of stress-response genes. In
addition, the presence of apoptotic hepatocytes in HCV-infected
mice suggests that liver injury can occur in the absence of an
adaptive HCV-specific immune response.genes was also higher between mice containing the same
donor hepatocytes than between mice containing different
hepatocytes (unpublished data). Since all animals were
inoculated with the same HCV (þ) serum, infected for similar
lengths of time, and in general showed similar serum HCV
RNA levels (Table 1), these results suggest that host-speciﬁc
factors are inﬂuencing the response to HCV infection.
HCV Infection in Mice Stimulates Innate Antiviral Signaling
Pathways
Analysis of the expression of genes encoding proteins
involved in interferon (IFN) signaling pathways and genes
known to be transcriptionally regulated by IFN has shown
that chronically infected HCV individuals show evidence of
an IFN response [5,16]. Gene expression analysis of liver
tissue from HCV-infected mice also demonstrated an up-
regulation of many known IFN-stimulated genes (ISGs). These
included key genes associated with the IFN-signaling pathway,
such as STAT1, IRF9, OAS, Mx1, TLR3, major histocompat-
ibility complex (MHC) class I, and PKR (Figure 2A). There was
also an up-regulation of genes associated with the immuno-
proteasome, including PSME2, PSMB9, and USP18, which
plays a role in antigen processing and presentation on MHC
class I molecules. Many of the up-regulated ISGs in HCV-
infected mice are also induced during the acute phase of
HCV infection of chimps as well as chronically infected
patients [5–7,9].
The up-regulation of ISGs was seen when the HCV-infected
liver tissue was compared with either donor-matched unin-
fected tissue (Figure 2A) or a reference pool of normal,
uninfected human tissue (data not shown). In contrast, liver
tissue from uninfected mice did not show an up-regulation of
these genes, demonstrating that the induction of IFN-
inducible genes is speciﬁc to HCV and not the result of the
isolation and transplantation of the human hepatocytes into
the mice (unpublished data). Quantitative PCR analysis of a
number of the IFN-regulated genes demonstrated a good
correlation with the gene expression data from the micro-
arrays (Figure 2B), although the ratios calculated from RT-
PCR generally exceeded those obtained using microarrays.
Interestingly, the use of mouse-speciﬁc probes for RT-PCR
analysis also demonstrated an induction of the IFN response
in the mouse hepatocytes, although in general at a much
lower level of induction than that seen in the human
hepatocytes from the same mouse (Figure 2C).
Although all HCV-infected mice showed evidence of
induction of innate antiviral signaling pathways, the response
was variable between mice, most notably between mice
containing hepatocytes from different donors (Figure 2A).
This is particularly interesting as the mice were all inoculated
with equal amounts of the same human serum containing
HCV genotype 1a. The IFN response appeared to be
independent of viral factors including serum HCV titers
and length of infection. For example, animals C585 and B473
had comparable serum HCV titers and lengths of infection,
yet mouse B473 showed a much stronger induction of IFN-
regulated genes. In addition, mouse D196 had only been
infected for approximately 4 wk, yet showed a very strong IFN
response, as indicated by the number and level of induction
of ISGs. Although the host response was variable between
mice, it was signiﬁcantly more similar between mice which
were transplanted with the same donor hepatocytes, animals
C585 and C572 (Figure 2A). In addition, individual samples
from the same liver showed remarkably similar induction of
ISGs, in both the identity of ISGs and level of induction.
Interestingly, there appeared to be an inverse association
between the total number of differentially regulated genes
and the number of up-regulated IFN genes. Animals with high
numbers of differentially expressed genes (C585 and C572)
tended to have lower numbers of induced IFN-regulated
genes, while animals with low numbers of differentially
expressed genes (B473 and D196) tended to have high
numbers of induced IFN-regulated genes (Figure 3). It is
possible that induction of an effective innate antiviral
response during the acute phase of HCV infection can limit
the spread of infection throughout the liver and/or the level
of HCV replication in already infected hepatocytes. This may
correlate with a less pronounced effect on the host cell as
measured by fewer changes in intrahepatic gene expression.
In support of this, quantitation of the intrahepatic HCV viral
loads indicated that a strong IFN response was generally
associated with lower levels of HCV RNA, whereas a weak IFN
Figure 1. Global Gene Expression Analysis of HCV-Infected Mice
Two-dimensional hierarchical clustering was done using Resolver System
software with an agglomerative algorithm, average link heuristic criteria,
and Cosine correlation metric. Each column represents gene expression
data from an individual experiment (either individual HCV-infected
mouse or individual liver sample) and the cluster represents genes that
showed a greater than 2-fold change (p ,0.05) in at least two
experiments. Genes shown in red were up-regulated, genes shown in
green were down-regulated, and genes shown in black indicate no
change in expression in HCV-infected tissue relative to donor-matched
uninfected tissue. Experiments using separate liver pieces from the same
HCV-infected mouse used the same uninfected sample as the reference.
DOI: 10.1371/journal.ppat.0020059.g001
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Host-Specific Response to HCV Infectionresponse was generally associated with higher levels of HCV
RNA (Figure 3). The main exception to this was animal D196,
which had a strong IFN response and relatively high levels of
intrahepatic HCV RNA. This animal also differed from the
remaining animal in that it was infected for a shorter period
of time (4 wk).
HCV Infection Affects Multiple Aspects of Lipid
Metabolism in a Host-Specific Manner
HCV-infected mice showed an induction in the expression
of many lipid metabolism genes. Similar to what is observed
in HCV-infected chimpanzees [9], this modulation appeared
to be host speciﬁc and tended to correlate with liver HCV
RNA levels. Two HCV-infected animals, B473 and D196, only
showed signiﬁcant up-regulation of PLA2G2A, an acute phase
protein which is associated with propagation of inﬂamma-
tion. In contrast, both C585 and C572, which contain the
same donor hepatocytes and, in general, had higher levels of
intrahepatic HCV RNA, showed an induction of a number of
genes encoding proteins/enzymes associated with many
aspects of lipid metabolism. Speciﬁcally, there was increased
expression of enzymes involved in fatty acid biosynthesis as
well as proteins involved in the transport of fatty acids,
suggesting that HCV infection was inducing fatty acid
biosynthesis (Figure 4A). Animals C585 and C572 exhibited
an up-regulation in the expression of many enzymes
responsible for cholesterol synthesis (FDPA, HMG-CS1,
HMG-CS2, HMG-CoA reductase), including some that cata-
lyze the rate-limiting steps in the synthesis pathway, such as
lanosterol synthetase (LSS) and squalene epoxidase (SQLE)
(Figure 4A). There was also an increase in the expression of
Figure 3. Association between IFN Response, HCV RNA Levels, and Effect
on Host Gene Expression in HCV-Infected Mice
Intrahepatic HCV RNA levels were determined by quantitative RT-PCR as
described in Materials and Methods. Total number of genes showing
increased expression in HCV-infected mice relative to donor-matched
uninfected mice is shown in gray bars, while the percent of induced
genes that are IFN regulated is shown using black triangles.
DOI: 10.1371/journal.ppat.0020059.g003
Figure 2. Expression of IFN-Inducible Genes in Human Liver Tissue from
HCV-Infected Mice
(A) Two-dimensional hierarchical clustering was done using Resolver
System software with an agglomerative algorithm, complete link
heuristic criteria, and Euclidean correlation metric. Each column
represents gene expression data from an individual experiment (either
individual HCV-infected mouse or individual liver sample). Genes were
selected as at least 2-fold regulated (p , 0.05) in at least one of seven
experiments. In the left panel, genes shown in red are up-regulated and
genes shown in green are down-regulated in HCV-infected tissue relative
to donor-matched uninfected tissue, while black indicates no change in
gene expression. In the right panel, genes whose regulation showed p .
0.05 are shown in gray.
(B) RT-PCR validation of the expression array data performed for six IFN-
inducible genes in a subset of HCV-infected mice. Data are shown as
log10 ratio and reflect the difference in expression between donor-
matched HCV-infected and naı ¨ve liver tissue.
(C) Expression of IFN-regulated genes in human and mouse liver tissue.
Comparison of gene expression levels of IFN-regulated genes by RT-PCR
analysis used either human- or mouse-specific probes. Data are shown as
log10 ratio and reflect the difference in expression between donor-
matched HCV-infected and naı ¨ve liver tissue.
DOI: 10.1371/journal.ppat.0020059.g002
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Host-Specific Response to HCV Infectionproteins involved in cholesterol transport and catabolism,
SORL1 and CYP7A1, suggesting that the hepatocytes are
trying to deal with the excess cholesterol by removing it from
the cell.
Interestingly, there was increased expression of genes
associated with peroxisomes, which contain enzymes for
respiration and cholesterol/lipid metabolism (Figure 4B),
speciﬁcally in animals in which both fatty acid and
cholesterol biosynthesis appeared to be increased. These
include peroxisome proliferator-activated receptor alpha
(PPARa) as well as genes known to be regulated by PPARa,
such as ANGPTL4, ECH1, PHYH, LBP, and ACOX3. In
addition, there was increased expression of enzymes which
mediate b-oxidation, the process of breaking down fatty acids
to generate energy. Animal C585 in particular had increased
expression of almost all the main enzymes involved in
mitochondrial b-oxidation (Figure 4B).
The reason for the host-speciﬁc nature of the regulation of
lipid metabolism genes is unclear. One possibility is that
certain donor hepatocytes had a higher baseline expression
of lipid biosynthesis genes, allowing for higher levels of HCV
replication during the initial stage of infection. However,
quantitative RT-PCR analysis did not reveal signiﬁcant
differences in the expression of ten lipid biosynthesis genes
among the uninfected animals (unpublished data). Alterna-
tively, it may be related to the nature of the IFN response.
There was an inverse association between the induction of
the host defense response and induction of fatty acid and
cholesterol biosynthesis genes in HCV-infected animals
(Figure 4C). Animals B473 and D196 both had strong IFN
responses and no induction of genes associated with fatty
acid or cholesterol biosynthesis. In contrast, animals C585
and C572 had a less intense IFN response but exhibited
induction of lipid biosynthesis genes. Although animals C585
and C572 contain the same donor hepatocytes and exhibited
very similar host responses to HCV infection, C572 appeared
to have a slightly stronger induction of the IFN response
(Figure 2A). Interestingly, C572 had a corresponding lower
level of intrahepatic HCV RNA and less induction of lipid
metabolism genes.
Potential Link between Disturbances in Lipid Metabolism
and Oxidative Stress
The gene expression data suggest that, in at least two of the
animals, there was an increase in both the synthesis and b-
oxidation of fatty acids. Lipid peroxidation produces reactive
oxidative species (ROS), such as H2O2, which can cause
damage to cellular proteins. In support of this, there is
Figure 4. Expression of Genes Associated with Lipid Metabolism in HCV-
Infected Mice
Expression of genes associated with fatty acid and cholesterol biosyn-
thesis (A) and peroxisomes, inflammation, and b-oxidation (B) that are at
least 2-fold regulated with p   0.05 in at least one of seven experiments.
See legend of Figure 1 for details on clustering, the applied color scheme
for the fold changes in the mRNA levels, and experiment representation.
(C) Association between host defense response and lipid biosynthesis.
Genes were selected as differentially expressed based on at least a 2-fold
change, p   0.05, and placed into functional categories using Fatigo
software. Graph depicts percent of differentially regulated genes
associated with each category for each experiment. Results from four
independent (individual animals) experiments comparing donor-
matched HCV-infected and naı ¨ve tissue are shown.
DOI: 10.1371/journal.ppat.0020059.g004
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Host-Specific Response to HCV Infectionevidence for oxidative stress speciﬁcally in animals which
showed an induction of the expression of enzymes in the b-
oxidation pathway (Figure 5). The level of induction of these
stress-response genes correlated with the expression of the b-
oxidation enzymes. Animal C585, which showed the greatest
induction, also showed the greatest induction of genes
associated with oxidative stress (Figure 5, pink text). In
contrast, the other samples showed either less effect (C572) or
no effect (B473 and D196) (Figure 5). Some of the genes listed
in Figure 5 are induced in response to DNA damage (shown
in blue text), possibly caused by ROS. Again, the induction of
oxidative stress appeared to correlate with a weak IFN
response.
Comparison of Host Response to Infection in HCV-
Infected Mice and Patients
One limitation of gene expression studies using biopsies
from HCV-infected individuals is the inability to ascertain
whether certain gene expression changes are the direct result
of viral replication or are the result of HCV-speciﬁc adaptive
immune responses. Because the mice used in this study are
incapable of generating an HCV-speciﬁc adaptive immune
response, comparison of HCV-induced gene expression
changes in these animals with gene expression changes in
HCV-infected patients provides a way of distinguishing viral
and immune-mediated effects. To facilitate a more direct
comparison, microarray experiments were performed where
HCV-infected liver tissue from patients (n¼5) and animals (n
¼ 5), as well as uninfected animals (n ¼ 3), was independently
compared to a common reference. The reference used was a
pool of RNA from eight normal uninfected liver samples
[3,5,17]. Morphological and histological examinations of
mouse tissue were also performed and the results compared
to results obtained from patient samples. Animals used for
histological analysis were independent of those used for the
gene expression studies.
When the gene expression proﬁles of HCV-infected
patients and mice were compared, the most notable differ-
ence was seen in the expression of immune cell–speciﬁc
genes. The mouse samples showed extensive down-regulation
of genes whose expression is mainly restricted to immune
cells, including T and B lymphocytes, natural killer cells, and
neutrophils (Figure 6). This down-regulation was apparent in
both HCV-infected and uninfected animals. Normal liver has
a small population of resident lymphocytes and it is possible
that a small percentage of this population is present in the
hepatocyte suspension that is transplanted into the animals.
However, the strong, uniform down-regulation of lympho-
cyte-speciﬁc genes suggests that if this occurs, the lympho-
cytes are not sustained long in the microenvironment of the
mouse liver, resulting in an underrepresentation of the genes
in the mouse liver tissue compared to normal liver. In
contrast, the patient samples actually showed an up-regu-
lation of some of these genes, likely due to the increased
inﬁltration of lymphocytes that occurs during chronic HCV
infection [5, 17] (Figure 6).
The expressions of genes from the IFN-signaling pathway
were strikingly similar between HCV-infected mice and
patients (Figure 7A and 7B, respectively), indicating that
HCV is triggering the same host innate antiviral response
pathways in both populations. Both showed an induction of
genes associated with creating an intracellular antiviral state,
such as those involved in antigen processing and presentation
on MHC class I molecules. They also showed similar induction
of ISGF3, IRF3, IRF1, and nuclear factor-jB target genes. This
suggests that despite the absence of an adaptive immune
response, this model is well suited for investigating the
interplay between HCV and the innate antiviral response.
Again, the only signiﬁcant differences between HCV-infected
animals and patients are seen in the expression of genes
speciﬁcally associated with immune cells, such as CD74 and
MHC class II, which is likely due to the absence of these cell
types in the mouse.
Liver sections from HCV-infected (n ¼ 10) and uninfected
(n ¼ 4) animals were subjected to histopathological analysis
and the results compared to clinical HCV specimens (n ¼ 5).
Immunohistochemical assays were performed to detect FAS
and activated Caspase-3 expression, and the results were
scored in a semiquantitative manner. Similar to what was
seen in liver biopsies from HCV-infected patients (Figure 8A),
FAS expression was increased in response to HCV infection
as shown by the strong membrane-associated staining using
an anti-FAS antibody (Figure 8B). In contrast, no staining was
observed in either uninfected animals (Figure 8C) or mouse
liver cells, indicating that FAS expression is speciﬁcally
induced by HCV infection and that the antibody is speciﬁc
to human FAS (unpublished data). Because FAS-associated
apoptosis, mediated by FAS-L expressing cytotoxic T lym-
phocytes, is thought to play a key role in HCV-associated liver
disease [18–20], the level of apoptosis was examined using
both Caspase-3 activation immunohistochemistry and lobular
apoptotic body count. Surprisingly, there was a trend toward
increasing signals of apoptosis in HCV-infected mice (apop-
totic bodies are indicated by arrows in Figure 8D) relative to
donor-matched uninfected animals. There also appeared to
be increased inﬂammatory activity (indicated by arrowheads
Figure 5. Association between Fatty Acid b-Oxidation and Expression of
Genes Implicated in the Stress Response
Expression of genes associated with stress response. See legend of
Figure 1 for details on clustering, the applied color scheme for the fold
changes in the mRNA levels, and experiment representation. Genes
implicated in oxidative stress are shown in pink text, while genes
induced in response to DNA damage are shown in blue text.
DOI: 10.1371/journal.ppat.0020059.g005
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Host-Specific Response to HCV Infectionin Figure 8D) in the hepatic lobules as well as hepatocyte
swelling, indicative of hepatocellular injury, in the HCV-
infected mice. The inﬂammatory cells consisted predom-
inantly of mononuclear and Kupffer cells. These ﬁndings are
similar to what is observed in early phase hepatitis C
infection, as well as in early recurrent hepatitis C after liver
transplantation [21–23]. Not surprisingly, Masson trichome
stain did not show any signiﬁcant portal ﬁbrosis in either
HCV-infected or uninfected mice (data not shown). Steatosis
was often observed speciﬁcally in the human hepatocytes of
the chimeric mice (seen in Figure 8) but was apparent in both
naı ¨ve and HCV-infected animals, indicating that it is speciﬁc
to the donor hepatocytes but not necessarily HCV infection.
Discussion
This study represents the ﬁrst report of transcriptional
proﬁling of HCV-induced gene expression changes in the
chimeric SCID-beige/Alb-uPA mouse model. It is unique in
that it examines the host response to a single HCV inoculum
in multiple donor hepatocytes and demonstrates for the ﬁrst
time that host factors play a key role in this response. Mice
containing hepatocytes from different donors exhibited very
different transcriptional changes despite being infected with
the same HCV inoculum. Animals containing the hepatocytes
from the same donor showed a much more similar response
and individual samples from the same liver were remarkably
similar. Together, these results suggest that host factors are
inﬂuencing the response to HCV infection.
Whereas all HCV-infected animals showed activation of the
host innate antiviral signaling pathways, as indicated by the
induction of ISGs, this response was highly variable between
mice containing hepatocytes from different donors. The
differences in the level of activation of ISGs appeared to be
independent of viral factors including serum HCV titers and
duration of infection. This variation in the host innate
antiviral response is consistent with previous gene expression
studies of liver biopsies from HCV-infected patients [5,17].
However, those studies were complicated by variation in both
virus inoculum and length of infection, making it difﬁcult to
determine the individual roles of viral and host factors in this
host response variation. Currently, much emphasis is placed
on the role of viral factors in regulating the host innate
response to infection, and there is evidence that HCV is able
to attenuate IFN signaling by multiple mechanisms (reviewed
in [24]). These mechanisms include HCV NS3/4A-mediated
antagonism of IRF3 activation through cleavage of adaptor
proteins of the RIG-I and TLR3 double-strand RNA signaling
pathways, both of which function to attenuate ISG expression
[25–29]. In addition, the HCV NS5A and E2 have been shown
to bind to and inhibit the catalytic activity of PKR, effectively
disrupting PKR-dependent translational control and signal-
ing actions [30–32]. The differences in the number and
intensity of induction of ISGs between animals containing
hepatocytes from different donors argue that host factors can
also inﬂuence the effectiveness of the innate immune
response.
Figure 6. Expression of Markers Associated with Immune Cells in HCV-Infected Mice and Patients
Expression of genes that were at least 2-fold regulated with p   0.05 in at least three of 13 experiments comparing uninfected mouse (blue text) and
HCV-infected liver tissue (mouse samples indicated by black text, patient samples indicated with red text) to a normal liver reference. See legend of
Figure 1 for details on clustering, the applied color scheme for the fold changes in the mRNA levels, and experiment representation.
DOI: 10.1371/journal.ppat.0020059.g006
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Host-Specific Response to HCV InfectionThe induction of ISGs in the mouse hepatocytes of HCV-
infected mice was somewhat surprising. Although the mouse
hepatocytes are not susceptible to HCV infection, the close
proximity of human and mouse hepatocytes [11] makes it is
feasible that this response in mouse hepatocytes is due to
cytokines released from neighboring HCV-infected human
cells.
The ability of HCV to maintain a persistent infection
despite activation of the innate antiviral response is intrigu-
ing. While transcriptional proﬁling indicates that there was
an IFN response in the livers of HCV-infected animals, it does
not provide information about where the response is coming
from. It is possible that the induction of ISGs measured on
the microarrays is originating primarily from uninfected
human cells, limiting the spread of HCV throughout the liver.
This would explain why mice which had strong IFN responses
tended to have lower levels of intrahepatic HCV RNA and
vice versa.
In general, the effect of HCV replication on host gene
expression in the mice was not that extreme, ranging from 60
to 653 differentially expressed genes in individual animals,
and was similar to what is observed in HCV-infected
chimpanzees [9]. This is perhaps not surprising, as it is
unlikely that HCV could establish a chronic infection
characterized by slowly progressive liver disease if infection
of hepatocytes severely affected the normal functions of the
cell. Interestingly, disturbances in the expression of lipid
metabolism genes were observed in two HCV-infected
animals transplanted with the same donor hepatocytes. Lipid
disturbances have been well documented in chronically
infected individuals, including hypocholesteremia and stea-
tosis (accumulation of fat droplets in hepatocytes), suggesting
that modulation of cellular lipid metabolism plays an
important role in the HCV life cycle [33–36]. HCV replication
during acute infection of chimpanzees is associated with a
host-speciﬁc regulation of lipid metabolism genes, including
increased expression of genes required for fatty acid and
cholesterol synthesis [6, 9]. Inhibition of cholesterol synthesis
by treatment with inhibitors of HMG-CoA reductase de-
creases HCV replication in the replicon system, indicating
that the cholesterol biosynthetic pathway regulates HCV
replication [9, 37]. Cholesterol is a vital component of cellular
membranes, and it is feasible that HCV induces cholesterol
biosynthesis to accommodate both progeny virion formation
and the production of intracellular membranes which are the
site of HCV replication. In addition, a geranylgeranylated
host protein, FBL2, was recently shown to form a complex
with NS5A which is required for HCV replication [38].
Induction of the cholesterol biosynthetic pathway would
therefore serve to increase biosynthesis of cholesterol and
isoprenoids (geranylgeranyl groups), both of which play
important roles in HCV replication. This might explain why
the greatest induction of these genes is seen in animals which
generally have higher levels of intrahepatic HCV RNA.
The mechanism by which HCV regulates the expression of
lipid metabolism genes is unknown. Many of the genes are
Figure 7. Induction of IFN-Signaling Pathways in HCV-Infected Mice and Patients
Pathway Builder (Protein Lounge) and the Pathway feature of Resolver were used to visualize the expression of genes from the IFN signaling pathway in
HCV-infected mice (A) and patients (B). The expression profiles of individual genes are shown in boxes, and each bar within the box represents one
experiment. Color schemes are as indicated in Figure 1. The reference for each microarray experiment was a pool of normal, uninfected human liver
tissue.
DOI: 10.1371/journal.ppat.0020059.g007
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Host-Specific Response to HCV Infectionregulated by the transcription factor sterol regulatory
element binding protein (SREBP), which binds to an SRE
element present in the promoters of target genes [39,40].
SREBP is normally localized to the endoplasmic reticulum
membrane and is activated by two cleavage events which
release it from the plasma membrane, allowing it to enter the
nucleus. This cleavage activation is regulated by sterol levels
through the action of SCAP, which regulates the activity of
the S1P, the protease which catalyzes the ﬁrst cleavage event
[40–42]. While the expression of SREBP was not signiﬁcantly
increased, the expression of genes encoding two proteins
responsible for regulating its activation, SCAP and S1P, was
increased speciﬁcally in the two animals which showed an
increase in SRE-inducible genes. The expression of SCAP was
increased 1.5-fold (p , 0.001), while SIP was increased greater
than 2-fold (p , 0.001). Increased expression of SCAP and
S1P may coincide with increased cleavage and release of
SREBP from the endoplasmic reticulum membrane, allowing
it to travel to the nucleus and promote transcription of SRE-
regulated genes.
Increased expression of lipid biosynthesis genes in HCV-
infected mice was associated with increased expression of
both b-oxidation enzymes and oxidative stress-inducible
genes, suggesting that lipid peroxidation was generating
higher levels of ROS in certain animals. The production of
excessive ROS potentially impacts both the development of
ﬁbrosis and HCC. Indeed, a preliminary study has demon-
strated changes in levels of proteins associated with lipid
metabolism and oxidative stress speciﬁcally in a liver biopsy
sample from a patient who developed ﬁbrosis following liver
transplantation [43]. These changes were not observed in
biopsy samples from patients who did not develop ﬁbrosis. It
is possible that the apoptosis of hepatocytes observed in
HCV-infected mice is linked to the oxidative stress that
results from increased lipid peroxidation. Indeed, enhanced
production of ROS can induce cell death through the
activation of transcription factors such as nuclear factor-jB
[44]. In addition, oxidative stress can initiate ﬁbrogenesis by
increasing procollagen type I gene expression [44].
Evidence of both oxidative stress and apoptosis indicates
that the liver pathology associated with chronic HCV
infection may not be caused exclusively by an HCV-speciﬁc
cell-mediated immune response. The fact that this effect
tended to be inversely related to the strength of the innate
antiviral response and corresponding HCV RNA level is
intriguing, although additional studies with a larger cohort of
animals is needed to verify this association. To date, there has
been no clear association between HCV level and severity of
liver disease [45,46]. However, there is circumstantial evi-
dence that suggests higher HCV levels may correlate with
enhanced ﬁbrosis. Immune suppression, including that
caused by immunosuppressive drugs and HIV coinfection, is
often associated with a more accelerated progression of liver
disease [47–52]. This is somewhat perplexing, given that the
pathology of HCV infection is thought to be primarily
immune mediated [2]. Both HIV coinfected individuals and
those on immunosuppressive drugs following liver transplant
tend to have higher serum levels of HCV RNA, presumably
due to the inability of the immune system to control HCV
replication [53]. Increased levels of intrahepatic HCV
A B
C D
Figure 8. Morphological and Immunohistochemical Analysis of HCV-Infected Mice
(A) Immunohistochemical staining for FAS in liver tissue from an HCV-infected patient showing diffuse strong membranous staining. Magnification
3200.
(B) Immunohistochemical staining for FAS in liver tissue from an HCV-infected mouse. Magnification 340.
(C) Immunohistochemical staining for FAS in liver tissue from an uninfected mouse. Magnification 3200.
(D) Hematoxylin and eosin staining of liver tissue from an HCV-infected mouse. The apoptotic bodies are indicated by arrows, and the inflammatory foci
are indicated by arrowheads. Magnification 3200.
DOI: 10.1371/journal.ppat.0020059.g008
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Host-Specific Response to HCV Infectionreplication have been shown to correlate with liver disease
severity [54]. In addition, a recent report describing tran-
scriptional proﬁling of serial biopsy samples from HCV-
infected patients following liver transplant demonstrated a
correlation between the host IFN response and development
of ﬁbrosis [5]. Similar to the ﬁndings in HCV-infected mice,
an impaired IFN response and accumulation of high numbers
of differentially expressed genes are observed speciﬁcally in
patients with rapidly progressing ﬁbrosis. These results
suggest that the nature of the innate antiviral response
during the acute phase of infection not only plays a role in
determining the outcome of infection but also is an
important contributing factor in the progression of liver
disease. Induction of a strong IFN response during the acute
phase of HCV infection may limit the spread of infection
throughout the liver and/or the level of HCV replication in
already infected hepatocytes to a level which does not
signiﬁcantly impact hepatocyte function. This argues that
suppression of HCV replication, even in the absence of
complete viral clearance, could improve clinical outcome.
Comparison of gene expression data from HCV-infected
mice and the transplant patients also suggests that despite the
lack of ﬁbrosis in HCV-infected mice, it is a valuable model in
which to investigate the role of host factors in the develop-
ment of liver disease. In particular, the model can be used to
study aspects of the innate antiviral immune response that
potentially limit HCV replication to minimize its effect on
cellular functions.
Materials and Methods
Dissection of mouse livers and isolation of RNA and genomic DNA.
All mice were treated according to Canadian Council on Animal Care
guidelines. SCID-beige/Alb-uPA mice were transplanted with human
primary hepatocytes and then infected with HCV as described
previously [10,12]. Mice were killed by cervical dislocation, and the
livers were excised, dissected into small pieces, and then snap frozen
in N2. Total RNA was then isolated according to a standard TRIZOL
procedure. Genomic DNA was isolated from the interphase and
phenol/chloroform phase according to the manufacturer’s speciﬁca-
tions (Invitrogen, Carlsbad, California, United States). Both RNA and
genomic DNA were isolated from the same samples.
PCR of human and mouse genomic DNA. Genomic DNA from the
liver of a SCID-beige/Alb-uPA mouse containing human hepatocytes
was ampliﬁed by PCR with primers speciﬁc for the fourth and ﬁfth
exons of the gene for the succinyl-CoA synthetase alpha subunit
(SCS-a). The PCR conditions were 0.01% (w/v) gelatin, 50 mM KCl, 1.5
mM MgCl2, 10 mM Tris (pH 8.3), 0.2 mM concentration each of dATP,
dGTP, dCTP, and dTTP, 2.5 U of Taq polymerase, and 0.25 lM each
of 59-TTGTGAATATGGCCAGGCATG (SCS-ex5) and 59-CAGGAG
CAACGGCTTCTGTC (SCS-ex4). The underlined nucleotide denotes
the position of the nucleotide that is present in the human sequence
but not in the mouse sequence. The PCR cycles were 5 min at 95 8C,
followed by 30 cycles of (30 s at 95 8C, 30 s at 45 8C, and 30 s at 72 8C).
The resulting PCR products were separated by electrophoresis in a
1.5% agarose gel, excised, puriﬁed using a QIAquick gel extraction kit
(Qiagen, Valencia, California, United States), cloned into pCR4
TOPO according to the manufacturer’s speciﬁcations (Invitrogen),
and sequenced. The cloned fragments from mouse and human were
452 bp and 384 bp, respectively. For measurement of the relative
amount of human and mouse SCS-a, the PCR conditions were as
follows: 1.2 lg of genomic DNA, 20 mM Tris (pH 8.4), 50 mM KCl, 2
mM MgCl2, 0.2 mM concentration each of dATP, dGTP, dCTP, and
dTTP, 2.5 U of Taq polymerase, and 0.25 lM concentration each of
SCS-ex4 and SCS-ex5. PCR cycles were 10 min at 95 8C followed by 40
cycles of (45 s at 95 8C, 45 s at 68 8C, and 45 s at 72 8C) and a ﬁnal
extension of 10 min at 72 8C. The cloned plasmids were used as
standards and were varied from 3.5 pg human/28 pg mouse to 28 pg
human/3.5 pg mouse per reaction. To determine the relative amount
of human SCS-a gene in the sample, the PCR products were
separated by electrophoresis using a 2.5% agarose gel and then
stained with ethidium bromide. The bands were quantiﬁed, a
correction was made for the size difference, and the results were
plotted on a standard curve generated using the plasmid controls.
Expression microarray format and data analysis. Microarray
format, protocols for probe labeling, and array hybridization are
described at http://expression.microslu.washington.edu. Brieﬂy, a
single experiment comparing two mRNA samples was done with
four replicate human 1A (V2) 22K oligonucleotide expression arrays
(Agilent Technologies, Palo Alto, California, United States) using the
dye label reverse technique. This allows for the calculation of mean
ratios between expression levels of each gene in the analyzed sample
pair, standard deviation, and p-values for each experiment. Spot
quantitation, normalization, and application of a platform-speciﬁc
error model were performed using Agilent’s Feature Extractor
software, and all data were then entered into a custom-designed
database, Expression Array Manager, and then uploaded into Rosetta
Resolver System 4.0.1.0.10 (Rosetta Biosoftware, Kirkland, Washing-
ton, United States) and Spotﬁre Decision Suite 7.1.1 (Spotﬁre,
Somerville, Massachusetts, United States). Data normalization and
the Resolver Error Model are described on the Web site (http://
expression.microslu.washington.edu). This Web site is also used to
publish all primary data in accordance with the proposed MIAME
standards [55]. Selection of genes for data analysis was based on a
greater than 95% probability of being differentially expressed (p  
0.05) and a fold change of 2 or greater. The resultant false-positive
discovery rate was estimated to be less than 0.1% (KAW, unpublished
data).
Immunohistochemistry. H e m a t o x y l i na n de o s i ns t a i n i n gw a s
performed according to the standard procedures. The inﬂammatory
activity and degree of ﬁbrosis in the liver were graded and staged,
respectively, according to a modiﬁed Batts and Ludwig scoring system
[56]. In particular, the inﬂammatory activity was scored in the portal
tracts and hepatic lobules, respectively. The degree of fatty change
was scored as 0, ,5%; 1, 6% to 33%; 2, 34% to 66%; and 3, .66%.
Average lobular apoptotic bodies were obtained by counting the
apoptotic bodies in ﬁve different ﬁelds at 310 objective. Immuno-
histochemical analyses were performed on parafﬁn sections from
formalin-ﬁxed material using monoclonal antibodies against FAS
(1:80 dilution; Novocastro, Newcastle, United Kingdom) and activated
caspase (1:200 dilution; Cell Signaling Technology, Beverly, Massa-
chusetts, United States). Following blockage of endogenous perox-
idase activities, dewaxed and rehydrated slides were subjected to
epitope retrieval performed in 0.01 M citrate (pH 6.0) in a
commercial microwave oven for 15 min. All stains were developed
using a standard avidin-biotin-peroxidase detection system (Vectas-
tain Elite ABC kit; Vector Laboratories, Burlingame, California,
United States) with 3,39-daminobenzidine-4 HCl as chromogen.
Immunohistochemical studies for FAS and activated Caspase-3 were
assessed in a semiquantitative fashion. Brieﬂy, the intensity of FAS
and activated Caspase-3 staining was graded as 0, none; 1, 1% to 25%;
2, 26% to 50%; 3, 51% to 75%; and 4, 76% to 100%. Masson trichome
stain was performed according to routine procedures.
Quantitative RT-PCR. Quantitative RT-PCR was used to validate
the gene expression changes and measure intrahepatic HCV RNA.
Total RNA samples were treated with DNA-free DNase Treatment
and Removal Reagents (Ambion, Austin, Texas, United States).
Reverse transcription was performed using random hexamer primers
and Taqman RT reagents (Applied Biosystems, Foster City, Califor-
nia, United States). RT-PCR was performed using an ABI 7500 Real
Time PCR system and Taqman chemistry. Each target was run in
quadruplicate with Taqman 2X PCR Universal Master Mix and a 20-ll
total reaction volume. Primer and probe sets for relative quantiﬁca-
tion were selected from the Assays-on-Demand product list (Applied
Biosystems) including two endogenous controls: GAPDH and 18S
ribosomal RNA. Quantiﬁcation of each gene, relative to the
calibrator, was calculated by the instrument, using the equation
2
 DCT within the Applied Biosystems Sequence Detections Software
version 1.3. Probes used for analysis (Applied Biosystems) were
human genes: eukaryotic 18S rRNA (catalog No. Hs99999901_s1),
IFIT1 (catalog No. Hs00356631_g1), ITITM1 (catalog No.
Hs00705137_s1), MX1 (catalog No. Hs00182073_m1), OAS2 (catalog
No. Hs00159719_m1), OASL (catalog No. Hs00388714_m1), and
STAT1 (catalog No. Hs00234829_m1); and mouse genes: IFIT1
(catalog No. Mm00515153_m1), IFIT1 (catalog No.
Mm00515153_m1), IFITM1 (catalog No. Mm00850040_g1), MX1
(catalog No. Mm00487796_m1), OAS2 (catalog No.
Mm00460961_m1), OASL (catalog No. Mm00496187_m1), and
STAT1 (catalog No. Mm00439518_m1).
Primer and probe sets for absolute quantiﬁcation of intrahepatic
viral load were designed based on sequences of HCV 1a armored
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Host-Specific Response to HCV InfectionRNA (Ambion Diagnostics, Austin, Texas, United States) using Primer
Express (version 3). A standard curve was made from six serial
dilutions of HCV 1a armored RNA (Ambion Diagnostics) with a
known viral copy number. The PCR efﬁciency was determined by the
slope of the standard curve Standard curve analysis and viral load
weres determined using the Applied Biosystems SDS Software 1.3
(Applied Biosystems). Total RNA was DNase treated prior to cDNA
synthesis via reverse transcription, and all samples were processed
with equal mass amounts of total RNA [57]. All measurements were
taken in quadruplicate with negative and nontemplate controls.
Primer and probe sets consisted of forward: CAC TCC CCT GTG
AGG AAC TAC TG; reverse: GCT GCA CGA CAC TCA TAC TAA CG;
and probe: 6FAM-TTC ACG CAG AAA GC-MGBNFQ, and were
designed from the 59 UTR using Primer Express 3.0 (Applied
Biosystems). Quantiﬁcation of HCV RNA levels was performed on
the same total RNA sample that was used for the microarray
experiments.
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